Pharmacology and clinical experience with simvastatin (Q34240784)

31 July 2017

1 reference

title

Pharmacology and clinical experience with simvastatin (English)

1 reference

31 July 2017

1 reference

ChEBI release 2020-05-28

1 reference

Hess DC

1

1 reference

31 July 2017

Fagan SC

series ordinal

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 January 2001

1 reference

Expert Opinion on Pharmacotherapy

31 July 2017

1 reference

31 July 2017

2

1 reference

31 July 2017

1

1 reference

31 July 2017

153-163

1 reference

Atherosclerosis — An Inflammatory Disease

31 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.153

Mechanism of calcification in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.153

Coronary plaque disruption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.153

Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.153

A receptor-mediated pathway for cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.153

Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.153

Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.153

Clinical pharmacokinetics and practical applications of simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.153

Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.153

Statins and peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.153

Stimulation of bone formation in vitro and in rodents by statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.153

HMG-CoA reductase inhibitors and the risk of fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.153

Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.153

Long-term safety and efficacy profile of simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.153

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.153

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.153

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.153

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.153

Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.153

Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.153

Pravastatin Therapy and the Risk of Stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.153

The design of a prospective study of pravastatin in the elderly at risk (PROSPER)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.153

ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.29.1346

Identifiers

DOI

10.1517/14656566.2.1.153

1 reference

release_cclcx2k6szcjbcscq2y7r2esgy

31 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/cclcx2k6szcjbcscq2y7r2esgy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference